Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Accolade And 2 Other US Penny Stocks With Growth Potential

In This Article:

As the U.S. stock market experiences a stumble in its recent rally, particularly with technology shares sliding, investors are keenly observing economic indicators and Federal Reserve policies for future direction. Amidst these fluctuations, penny stocks—though an older term—still represent a viable investment area for those interested in smaller or newer companies that might offer growth potential. By focusing on penny stocks with strong financial health and clear growth trajectories, investors can uncover opportunities that may provide both stability and upside potential.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.802475

$5.67M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$167.65M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.72

$143.18M

★★★★★☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.22

$8.3M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$4.90

$702.04M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.58

$51.81M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.952

$85.54M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.84

$424.98M

★★★★☆☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Accolade

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Accolade, Inc. develops and provides personalized, technology-enabled solutions to help individuals navigate the healthcare system and workplace benefits in the United States, with a market cap of approximately $303.62 million.

Operations: Accolade's revenue is primarily derived from its Pharmacy Services segment, which generated $441.03 million.

Market Cap: $303.62M

Accolade, Inc., with a market cap of US$303.62 million, presents both opportunities and challenges typical of penny stocks. The company has reported revenue growth, with recent quarterly sales reaching US$106.36 million, but remains unprofitable with a net loss of US$23.93 million for the same period. Its short-term assets exceed liabilities significantly, providing financial stability in the near term. However, shareholder dilution and ongoing losses highlight risks associated with its current valuation and profitability outlook over the next three years. Despite these challenges, Accolade's experienced management team continues to navigate the complex healthcare sector effectively.